"CTNI-08: Tucatinib, Trastuzumab, and Capecitabine with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR): A Multicenter Phase 1 Clinical Trial" by Manmeet Ahluwalia

Presentation

CTNI-08: Tucatinib, Trastuzumab, and Capecitabine with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR): A Multicenter Phase 1 Clinical Trial

Neuro-oncology

Manmeet Ahluwalia, Miami Cancer Institute
Ahmad Ozair, Miami Cancer Institute
Atulya Khosla, Miami Cancer Institute
Shreyas Bellur, Miami Cancer Institute
Rupesh Kotecha, Miami Cancer Institute
Michael McDermott, Miami Neuroscience Institute
Minesh Mehta, Miami Cancer Institute
Ana Cristina Sandoval Leon, Miami Cancer Institute
Reshma Mahtani, Miami Cancer Institute

Publication Date

11-15-2023

Presented At:

Annual Meeting. Society for Neuro-Oncology (SNO)

Content Type

Presentation

Publisher's Site:

View at Publisher Website

Additional Authors:

Additional authors and institutional affiliations

Citation Information

Ahluwalia, M., Ozair, A., Khosla, A., Bellur, S., Kotecha, R., McDermott, M., Mehta, M., Sandoval-Leon, A., Mahtani, R., & Peereboom, D. (2023). CTNI-08: Tucatinib, Trastuzumab, and Capecitabine with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR): A Multicenter Phase 1 Clinical Trial. Neuro-Oncology, 25(Supplement_5), v74-v74. https://doi.org/10.1093/neuonc/noad179.0290